紫杉醇脂质体联合替吉奥新辅助化疗治疗进展期胃癌疗效观察

Clinical Observation on Treatment of Neoadjuvant Chemotherapy of Paclitaxel Liposome Combined with S-1 for Advanced Gastric Cancer

目的探讨紫杉醇脂质体联合替吉奥新辅助化疗治疗进展期胃癌疗效。方法 32例病理诊断确诊为Ⅱ~Ⅲ期进展期胃癌患者,未接受过抗肿瘤治疗,无严重心肺疾病。采用DS方案:紫杉醇脂质体125mg/m2静脉滴注,d 1;替吉奥胶囊,每次60 mg/m2,Bid,口服,d 1~14;每21d重复,共3~4个周期,评估疗效并观察不良反应。结果 32例患者中完全缓解(CR)1例,部分缓解(PR)28例,稳定(SD)2例,进展(PD)1例,客观缓解率(OR)为90.6%(29/32)。发生骨髓抑制13例(40.62%),胃肠道反应16例(50%)。均接受了根治性切除,无围手术期死亡病例。结论紫杉醇脂质体联合替吉奥新辅助化疗治疗进展期胃癌安全可行。

Objective To assess the efficacy and toxicity of liposome-paclitaxel and S-1 combination therapy for advanced gastric cancer.Methods The chemotherapy regime was 125 mg/m2 liposome-pacli-taxel given on day 1,combined with S-1 60 mg/m2 twice a day on days 1-14,taking 3 weeks as one treat-ment cycle.The patients continued to be treated until receiving three or four cycles or until developing nei-ther progressive disease nor untolerated toxicity.Resaults The total 32 patients with advanced gastric cancer were enrolled in primary treatment,with pathological diagnosis and staging of Ⅱ-Ⅲ period.Mean-while,all patients received radical resection without perioperative death.The results showed 1 case a-chieved CR,28 cases achieved PR with an ORR of 90.6%.2 case achieved SD,2 cases achieved PD. The hematological toxicities were neutropenia which occurred in 13 (40.62%).Nausea, vomiting oc-curred in 16 (50%)patients.Conclusions The combination regimen of liposome-paclitaxel and S-1 is ef-fective and well tolerated for patients with advanced gastric carcinoma,especially for primary treatment cases.